Clinical Trials Browser

OTHER × Carcinoma, Squamous Cell × temsirolimus × Clear all

NCT01009203 2015-08-10

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

Phase 2 Terminated

13 enrolled 8 charts

Carcinoma, Squamous Cell